180 related articles for article (PubMed ID: 28522345)
21. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
22. Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Barba P; Valcárcel D; Pérez-Simón JA; Fernández-Avilés F; Piñana JL; Martino R; López-Anglada L; Rovira M; Garcia-Cadenas I; Novelli S; Carreras E; López Corral L; Sierra J
Biol Blood Marrow Transplant; 2013 Apr; 19(4):597-601. PubMed ID: 23305680
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
24. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
25. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
[TBL] [Abstract][Full Text] [Related]
26. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Brammer JE; Stentz A; Gajewski J; Curtin P; Hayes-Lattin B; Kovacsovics T; Leis JF; Meyers G; Nemecek E; Subbiah N; Frires R; Palmbach G; Avraham GP; Slater S; Maziarz RT
Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
[TBL] [Abstract][Full Text] [Related]
27. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
29. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
30. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
31. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
32. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
33. Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies.
Mori T; Tanaka M; Kobayashi T; Ohashi K; Fujisawa S; Yokota A; Fujita H; Nakaseko C; Sakura T; Nannya Y; Takahashi S; Kanamori H; Kanda Y; Sakamaki H; Okamoto S;
Biol Blood Marrow Transplant; 2013 Mar; 19(3):486-91. PubMed ID: 23253560
[TBL] [Abstract][Full Text] [Related]
34. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Lam W; Storek J; Li H; Geddes M; Daly A
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.
Salit RB; Oliver DC; Delaney C; Sorror ML; Milano F
Biol Blood Marrow Transplant; 2017 Apr; 23(4):654-658. PubMed ID: 28189904
[TBL] [Abstract][Full Text] [Related]
37. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
38. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Kawamata T; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1150-5. PubMed ID: 24727335
[TBL] [Abstract][Full Text] [Related]
39. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
